The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.38
Bid: 2.21
Ask: 2.47
Change: 0.00 (0.00%)
Spread: 0.26 (11.765%)
Open: 2.38
High: 0.00
Low: 0.00
Prev. Close: 2.38
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Incanthera - Comm'l Skincare Deal/£1M Fundraise

18 Dec 2023 07:15

RNS Number : 0696X
Immupharma PLC
18 December 2023
 

18 December 2023

 

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Incanthera Secures Commercial Skincare Deal & £1M Fundraise

 

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is delighted to highlight the announcement issued this morning by Incanthera plc ("Incanthera"), the dermatology and oncology specialist, in which ImmuPharma currently holds a 12.7% shareholding.

 

Within the announcement, Incanthera announces a significant commercial skincare deal with Marionnaud (part of the A.S. Watson Group) initially across Europe and further roll outs in Asia. It confirmed that this deal is expected to generate significant revenues and profitability for Incanthera, in 2024 and beyond.

 

In conjunction Incanthera announces that it has concluded a successful fundraise of £1,000,000, with new and existing institutional investors which was oversubscribed, and is priced at £0.07, a premium of 11.1% to the mid-market price at the close of trading on Friday 15 December 2023.

 

Incanthera trades on Aquis Stock Exchange ("AQSE") under the ticker (AQSE:INC). For full details of the announcement, please visit Incanthera's website: https://incanthera.com/investors/regulatory-news/.

 

Commenting on Incanthera's announcement, Dr Tim Franklin, COO of ImmuPharma said: "As a major shareholder in Incanthera, we are delighted with this significant milestone, which highlights the enormous opportunities within Incanthera's revolutionary skincare range."

 

 

For further information please contact:

 

ImmuPharma PLC (www.immupharma.com)

Dr Tim Franklin, COO

Lisa Baderoon, Head of Investor Relations

+44 (0) 207 206 2650

 

+ 44 (0) 7721 413496

 

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge, Bob Pountney

 

SI Capital (Joint Broker)

Nick Emerson

 

+44 (0) 203 368 3550

 

 

+44 (0) 203 650 3650/51

 

 

+44 (0) 1483 413500

 

 

 

 

 

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor?), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

 

For additional information about ImmuPharma please visit www.immupharma.co.uk

 

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

 

 

About Incanthera plc

 

Incanthera is a specialist company focused on innovative technologies in dermatology and oncology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading specialists and academic institutions as well as its in-house development team.

 

Incanthera originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford. Incanthera's strategy is to develop each candidate in its portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

For more information on Incanthera please visit: www.incanthera.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUBORRORUUAUA
Date   Source Headline
14th Sep 202210:04 amRNSWritten Response received from the FDA
7th Sep 20228:25 amRNSExercise of Options
31st Aug 20227:00 amRNSFDA response for Type C Meeting - update
30th Aug 202211:29 amRNSExercise of Options
24th Aug 20228:11 amRNSExercise of Options
17th Aug 20226:12 pmRNSTR-1 Notification of major holdings
16th Aug 20228:03 amRNSTotal Voting Rights
11th Aug 20227:00 amRNSResult of Broker Option / PDMR Dealings
4th Aug 20227:00 amRNSInvestor Presentation - Investor Meet Company
3rd Aug 20224:40 pmRNSSecond Price Monitoring Extn
3rd Aug 20224:35 pmRNSPrice Monitoring Extension
3rd Aug 20224:33 pmRNSSubscription/Placing to raise £1.1m; Broker Option
26th Jul 20224:41 pmRNSSecond Price Monitoring Extn
26th Jul 20224:35 pmRNSPrice Monitoring Extension
11th Jul 20227:00 amRNSInitiation of Research
7th Jul 20227:00 amRNSConfirmed FDA response date for Type C Meeting
28th Jun 20225:44 pmRNSAdmission of new ordinary shares of £0.01
28th Jun 202211:42 amRNSResult of AGM
27th Jun 20227:00 amRNSUpdate on Lupuzor
20th Jun 20223:22 pmRNSHolding(s) in Company
1st Jun 20227:00 amRNSNotice of AGM & Annual Report & Accounts
25th May 20227:00 amRNSFinals results for y/e 31 December 2021
4th May 20227:00 amRNSUPDATE on LUPUZOR™ PROGRESS to PHASE 3 with AVION
13th Apr 20227:00 amRNSUPDATE on P140 (LUPUZOR™) clinical progress
7th Feb 20227:00 amRNSLUPUZOR UPDATE
10th Jan 20227:00 amRNSTR-1: Notification of major holdings
5th Jan 20229:53 amRNSTR-1: Notification of major holdings
24th Dec 20218:34 amRNSHolding(s) in Company
20th Dec 20217:00 amRNSSubscriptions and Placing to raise £3.55 million
15th Dec 20214:35 pmRNSPrice Monitoring Extension
7th Dec 20214:41 pmRNSSecond Price Monitoring Extn
7th Dec 20214:36 pmRNSPrice Monitoring Extension
29th Nov 20217:00 amRNSCOLLABORATION WITH IMPERIAL COLLEGE LONDON
18th Nov 20217:00 amRNSCorporate Update
8th Nov 20214:41 pmRNSSecond Price Monitoring Extn
8th Nov 20214:36 pmRNSPrice Monitoring Extension
11th Oct 20214:35 pmRNSPrice Monitoring Extension
1st Oct 20217:00 amRNSEuronext Delisting
30th Sep 20217:15 amRNSPROF. SYLVIANE MULLER AWARDED ‘LEGION D’HONNEUR’
29th Sep 20217:30 amRNSInterim Results for the 6months ended 30 June 2021
29th Sep 20217:00 amRNSCorporate Update
22nd Sep 20214:36 pmRNSPrice Monitoring Extension
24th Aug 202111:07 amRNSDirector/PDMR Shareholding
20th Aug 20214:40 pmRNSSecond Price Monitoring Extn
20th Aug 20214:35 pmRNSPrice Monitoring Extension
19th Aug 20214:35 pmRNSPrice Monitoring Extension
17th Aug 20218:50 amRNSNotification of Major Holdings
12th Aug 20217:00 amRNSFDA approves the Lupzuor™ PK study
10th Aug 20214:40 pmRNSSecond Price Monitoring Extn
10th Aug 20214:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.